Rockwell Medical Announces Pricing of $17.5 Million Public Offering of Common Stock
June 18 2019 - 8:00AM
Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the
“Company”), a biopharmaceutical company dedicated to improving
outcomes for patients with anemia, with an initial focus on
end-stage renal disease (ESRD) and chronic kidney disease (CKD),
today announced the pricing of its previously announced
underwritten public offering of 5,833,334 shares of its common
stock at a public offering price of $3.00 per share. All of
the shares of common stock are being offered by Rockwell
Medical. In addition, Rockwell Medical has granted the
underwriters a 30-day option to purchase up to an additional
875,000 shares of its common stock at the public offering price
less the underwriting discounts and commissions. The Company
expects to receive gross proceeds of approximately $17.5 million,
before deducting the underwriting discounts and commissions and
estimated offering expenses payable by the Company, and assuming no
exercise of the underwriters’ option to purchase additional
shares. Rockwell Medical anticipates using the net proceeds
from the offering for the commercialization of Dialysate Triferic
and I.V. Triferic, research and development and general corporate
purposes.
The offering is expected to close on or about June 20, 2019,
subject to the satisfaction of customary closing conditions.
Piper Jaffray & Co. and Cantor Fitzgerald & Co. are
acting as book-running managers and H.C. Wainwright & Co. is
acting as lead manager for the offering.
The securities described above are being offered by Rockwell
Medical pursuant to a shelf registration statement previously filed
with and declared effective by the Securities and Exchange
Commission (the “SEC”). A preliminary prospectus supplement
and the accompanying prospectus related to the offering have been
filed with the SEC and are available on the SEC’s website at
www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus relating to this offering may be
obtained, when available, from: Piper Jaffray & Co.,
Attn: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email
at prospectus@pjc.com; or Cantor Fitzgerald & Co., Attn:
Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022;
Email: prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Rockwell Medical
Rockwell Medical is a biopharmaceutical company dedicated to
improving outcomes for patients with anemia, with an initial focus
on end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Rockwell Medical’s exclusive renal drug therapy, Triferic, supports
disease management initiatives to improve the quality of life and
care of dialysis patients and is intended to deliver safe and
effective therapy, while decreasing drug administration costs and
improving patient convenience. The Company has developed multiple
formulations of Triferic, the only FDA-approved therapeutic
indicated for iron replacement and maintenance of hemoglobin in
hemodialysis patients. The Company’s strategy is to bring its
therapeutics to market in the United States and to utilize partners
to develop and commercialize such therapeutics in international
markets. Rockwell Medical is also an established manufacturer,
supplier and leader in delivering high-quality hemodialysis
concentrates/dialysates to dialysis providers and distributors in
the U.S. and abroad.
Forward Looking Statements
Certain statements in this press release may constitute
“forward-looking statements” within the meaning of the federal
securities laws, including, but not limited to, Rockwell Medical’s
expectations regarding the consummation of the offering and the
satisfaction of customary closing conditions with respect to the
offering and the anticipated use of the net proceeds of the
offering. Words such as “may,” “might,” “will,” “should,”
“believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,”
“plan,” “potential,” “predict,” “forecast,” “project,” “plan”,
“intend” or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While Rockwell Medical believes these forward-looking statements
are reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties (including, without
limitation, those set forth in Rockwell Medical’s SEC filings),
many of which are beyond our control and subject to change. Actual
results could be materially different. Risks and uncertainties
include: changes as a result of market conditions or for other
reasons, the risk that the offering will not be consummated, and
the impact of general economic, industrial or political conditions
in the United States or internationally, as well as those risks
more fully discussed in Rockwell Medical’s SEC filings.
Accordingly, you should not place undue reliance on these
forward-looking statements. Rockwell Medical expressly disclaims
any obligation to update or alter any statements whether as a
result of new information, future events or otherwise, except as
required by law.
Triferic® is a registered trademark of Rockwell Medical,
Inc.
Contact
Investor Relations:Lisa M. Wilson, In-Site Communications,
Inc.T: 212-452-2793E: lwilson@insitecony.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024